Incretin-related metabolic regulators - Hormone analogues
InvivoGen offers a growing range of biologically active incretin and hormone receptor agonists for studying metabolic pathways driven by incretin hormones.
Each ligand is tested for potency and specificity toward its target receptor using our proprietary cell-based metabolic bioassays. They are verified to be free of bacterial contaminants, including endotoxins. This guarantees reliable experimental performance across a range of applications, from mechanism-of-action studies to therapeutic development and screening of next-generation metabolic drugs. Moreover, the ligands are suitable for in vivo studies, as they are guaranteed sterile, verified using a European Pharmacopoeia-based (2.6.1) sterility assay.
Incretins are gut-derived peptide hormones, primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), secreted after nutrient intake to enhance glucose-dependent insulin release from pancreatic β cells. Together with glucagon (GCG), they form an integrated hormonal network that maintains glucose and energy balance. They have emerged as key therapeutic targets in diabetes and obesity research, ranging from GLP-1 analogs like Semaglutide (Ozempic®/Wegovy®) to dual and triple agonists (Retatrutide) that synergistically enhance glycemic control and promote weight loss.
Key features
- Functionally validated using proprietary incretin-bioassays
- High purity and guaranteed sterile
- Tested for hormone receptor specificity
- Endotoxin tested
Since these metabolic hormones are biologically active molecules, their functions can’t be fully understood through physicochemical analyses alone. Thus, our growing library of incretin and hormone receptor agonists is thoroughly validated using our proprietary incretin reporter cells, ensuring that each molecule delivers consistent and biologically relevant activity.
Illustration on this page were created with BioRender.com.
